Article Sidebar
Published:
Mar 7, 2017Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Analysis of the effect of Qizhuyigan on liver function in a mouse model of immunological liver injury
Abstract
Purpose: To assess the protective effect of Qizhuyigan capsules containing an herbal mixture on liver function in a mouse model of immunological liver injury and to explore the mechanism of action.
Methods: One hundred and twenty mice were randomly divided into four groups: control, test, bifendate, and Qizhuyigan. Immunological liver injury was induced in all groups except the control group. Mice in the control group and the test group were gavaged with 2.5 g/kg tap water, mice in the bifendate group were gavaged with 12 mg/kg bifendate in water, and mice in the Qizhuyigan group were gavaged with 1,000 mg/kg of an aqueous solution containing the contents of a Qizhuyigan capsule. The gavage continued for 10 days. Changes in liver function-related indices, such as the levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), malonaldehyde (MDA), superoxide dismutase (SOD), tumor necrosis factor α (TNF-α), and interleukin 6 (IL-6), were assessed.
Results: Compared with the test and bifendate groups, the Qizhuyigan group exhibited lower serum ALT (98.3 U/L ± 8.7 U/L vs. 224.7 U/L ± 18.4 U/L vs. 132.8 U/L ± 9.4 U/L); AST (165.5 U/L ± 12.1 U/L vs. 362.6 U/L ± 16.6 U/L vs. 224.6 U/L ± 12.2 U/L); and MDA levels (12.7 ± 2 μmol/L vs. 31.3 ± 6.60 μmol/L vs. 14.4 ± 2.3 μmol/L); a higher SOD level; and reduced TNF-α and IL-6 levels. The differences of the above indices had statistical significance (p < 0.05).
Conclusion: Qizhuyigan exerted a protective effect in a mouse model of immunological liver injury.
Keywords: Qizhuyigan capsule, Immunological liver injury, Biochemical parameters
